References
- Fenton WS, Blyler CR, Heinssen Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 23,637–651 (1997).
- Kane J. Compliance issues in out-patient treatment. j Clin. Psychopharmacology5, 22s-27s (1985).
- Young JL, Zonana HV Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull. Am. Acad. Psychiatry Law 14,105–122 (1986).
- Casper ES, Regan JR. Reasons for admission among six profile subgroups of recidivists of in-patient services. Can. Psychiatry38, 657–661 (1993).
- Lindqvist P, Allebeck P. Schizophrenia and crime. A longitudinal follow-up of 644 schizophrenics in Stockholm. Br. Psychiatry 157,345–350 (1990).
- Mitchell EW. Does psychiatric disorder affect the likelihood of violent offending? A critique of the major findings. Med. Sci. Law 39,23–30 (1999).
- Tam E, Engelsmann F, Fugere R. Patterns of violent incidents by patients in a general hospital psychiatric facility. Psychiatr. Serv. 47,86–88 (1996).
- Bruno S, Silver S. Chapter 408. New York State Constitution. (1999).
- Kohl M. New York state moves toward involuntary residential commitment of the mentally ill. Psychiatric Timer, 16,30–32 (1999).
- Brabbins C, Butler J, Bentall R. Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues [see comments]. Br. Psychiatry 168,540–544 (1996).
- Carpenter WT, Conley RR. Sense and nonsense: an essay on schizophrenia research ethics. Schizophr. Res. 35,219-225; discussion 227–236 (1999).
- Wong JG, Clare CH, Holland AJ, Watson PC, Gunn M. The capacity of people with a 'mental disability' to make a healthcare decision. Psych& Med. 30,295–306 (2000).
- Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int. Clin. Psychopharmacol. 9\(Suppl. 5), 17–20 (1995).
- Siegel SJ, Winey K, Gur RE et al. A role for surgically implantable long-term antipsychotic delivery systems in the treatment of schizophrenia. Neuropsychopharm. 26/6,817-823 (2002).
- Suzuki K, Price JC. Microencapsulation and dissolution properties of a neuroleptic in a biodegradable polymer, poly (d,1-lactide). j Pharm. Sci. 74,21-24 (1985).